CAMBRIDGE, Mass., May 22 /PRNewswire/ -- Xanthus Pharmaceuticals, Inc.,
a privately-held oncology drug development company, today announced that
John Lister-James, Ph.D. has joined the Xanthus management team as Vice
President, Development.
"John brings to Xanthus a track record of approved products and
advanced development projects, and is a recognized leader of
multi-disciplinary R&D teams in the discovery and development of diagnostic
and therapeutic products," stated Richard T. Dean, Ph.D., President and CEO
of Xanthus. "We expect that John's expertise and broad skill-set will play
a key role in the execution of our ongoing development programs in oncology
and autoimmune therapeutics."
John Lister-James joins Xanthus from the Schering AG group where he was
Vice President, Corporate CMC Development, Radiopharmaceuticals, at CIS-US,
Inc. and responsible for Corporate Chemistry, Manufacturing and Controls
(CMC) Development of radiopharmaceuticals. Previously, Dr. Lister-James was
responsible for Research, CMC and Nonclinical Development and Clinical
Research at Diatide Research Laboratories, a division of Berlex
Laboratories (also a subsidiary of Schering AG). Prior to its acquisition
by Berlex/Schering, Dr. Lister-James was Vice President, Science and
Technology at Diatide, Inc. Earlier, Dr. Lister-James held technical and
management positions at Centocor, where he supervised research and
development of radiolabeled monoclonal antibodies. While at Diatide, Dr.
Lister-James directed CMC/Nonclinical Development leading to the regulatory
approval of NeoTect(R)/NeoSpect(TM) and AcuTect(R), and directed R&D
activities leading to the discovery and early development of NeoTide(TM), a
radiotherapeutic product for the treatment of lung cancer.
Dr. Lister-James obtained his Ph.D. in Organic Chemistry from the
University of London and his B.Sc. (Honors) in Chemistry from Imperial
College, University of London. He conducted post-doctoral work at the
Massachusetts Institute of Technology and Harvard Medical School that
focused on the chemistry of technetium and its application in medical
imaging. He is a co-inventor of 60 U.S. patents and has co-authored over 35
peer-reviewed articles.
About Xanthus Pharmaceuticals, Inc.
Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel,
clinical-stage, small-molecule oncology candidates through a management
team whose accomplished track record encompasses all aspects of drug
development, from discovery through regulatory approval and
commercialization. The Company is applying its expertise both to advance
its current pipeline and expand it into indications of unmet medical need
beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.
Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc. -
kwatson@macbiocom.com or (508) 647-0209
Lisa Terry, Corporate Communications, Xanthus Pharmaceuticals, Inc. -
lisa.terry@xanthus.com or (617) 252-6105
SOURCE Xanthus Pharmaceuticals, Inc.
 back to top
Related links:
http://www.xanthus.com
CONTACT:
Kari Watson of MacDougall Biomedical
Communications, Inc., +1-508-647-0209, kwatson@macbiocom.com; or
Lisa Terry, Corporate Communications of Xanthus Pharmaceuticals,
Inc., +1-617-252-6105, lisa.terry@xanthus.com
|
